Treatment of patients infected with chronic hepatitis C genotype 2 and 3: More data, more questions?

Hepatology

Volumn 49, Issue 2, 2009, Pages 345-347

  Graziadei, Ivo W ^a   Vogel, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

BODY MASS; CLINICAL TRIAL; COST OF ILLNESS; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; EDITORIAL; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SHORT COURSE THERAPY; THROMBOCYTE COUNT; VIRUS LOAD; GENETICS; HEPATITIS C VIRUS; NOTE;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS;

EID: 61949143667     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22819     Document Type: Editorial

References (14)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
4. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39:1147-1171.
5. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006;130:225-230.
6. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-2617.
7. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
8. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132:103-112.
9. Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. HEPATOLOGY 2008;47:35-42.
10. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. HEPATOLOGY 2008;47:1837-1845.
11. Mangia A, Minerva N, Cozzolongo R, Agostinacchios E, Sogari F, Scotto G, et al. Determinants of relapse after a short (12 week) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic HCV genoytpe 2 or 3 infection. HEPATOLOGY 2009; doi: 10.1002/hep.22679.
12. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-559.
13. Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. HEPATOLOGY 2007;46:971-981.
14. Di Martino V, Richou C, Thevenot T, Sanchez-Tapias JM, Ferenci P. Modulations of a Peginterferon plus ribavirin duration according to HCV-genotype and virologic response at w4 and w12: Meta-analyses of RCTs with individual data [Abstract]. HEPATOLOGY 2008;48(Suppl):404A.